-transparent.png){kind=logo}
Platelet MAO-B levels have been investigated in seventeen consecutively diagnosed and previously untreated patients with idiopathic Parkinson's disease using the non-hydroxylated catecholamine, beta-phenylethylamine, as substrate. Patients with Parkinson's disease had MAO-B activity levels that were considerably higher than sex and age matched normal controls or patients with Motor neurone disease or Myasthenia gravis.
Related Publications
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
August 2009,
Neurochemical research,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
January 1993,
Journal of neural transmission. Parkinson's disease and dementia section,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
February 1996,
Biochemical Society transactions,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
February 2001,
Journal of neurology, neurosurgery, and psychiatry,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
January 2017,
CNS & neurological disorders drug targets,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
February 1986,
Journal of the neurological sciences,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
October 1990,
Journal of neurology, neurosurgery, and psychiatry,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
January 1993,
Advances in neurology,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
July 2005,
The Cochrane database of systematic reviews,
G B Steventon, and
S G Sturman, and
M T Heafield, and
R H Waring, and
J Napier, and
A C Williams
September 2004,
BMJ (Clinical research ed.),
